Johnson & Johnson Family Of Diabetes Companies Provides Diabetes Supplies To Children In Developing Countries | Johnson & Johnson
Johnson & Johnson Family of Diabetes Companies Provides Diabetes Supplies to Children in Developing Countries LifeScan, Inc. supplies one million test strips and encourages support for International Diabetes Federations Life for a Child program Milpitas, Calif., November 12, 2012 As part of the Johnson & Johnson Family of Diabetes Companies, LifeScan, Inc. announced today support of the International Diabetes Federations (IDF) Life for a Child program with a donation of one million OneTouch Brand test strips to children with diabetes in seven developing countries (Mali, Zimbabwe, Bangladesh, Nepal, Sri Lanka, Guyana, Guatemala). This donation represents the Johnson & Johnson Family of Diabetes Companies recognition of World Diabetes Day on Nov. 14. The Life for a Child program currently assists children and youth across the globe thanks to the support of many donors like Johnson & Johnson, said Dr. Graham Ogle, General Manager of Life for a Child. This donation will enable up to 1300 young people with diabetes in these seven countries to monitor their blood glucose at least twice daily for about a year. Many of these children have never had access to a meter before so this will be a tremendous support to them. We are committed to helping people with diabetes live a life without limits, and we are honored to support the IDFs Life for a Child program, said Michel Paul, Company Group Chairman for the Johnson & Johnson Family of Diabetes Companies. With the help of this program, we hope to improve the lives of children around the world who are struggling to manage their diabetes. In honor of World Diabetes Day on Nov. 14, we also hope to inspire others to learn more about the IDFs mission and to provide support for the Life for a Child program. Despite this donation and ma Continue reading >>
Johnson & Johnson Cautious In Outlook, Shops Diabetes Care
Johnson & Johnson cautious in outlook, shops diabetes care Johnson & Johnson edged above fourth-quarter profit expectations, helped by consumer goods and pharmaceutical growth, but the world's biggest health care products company also gave Wall Street a softer-than-expected 2017 earnings forecast. The maker of Band-Aids and prescription drugs also said Tuesday it was taking another step in restructuring its medical device segment by shopping its diabetes care businesses, which make test strips and insulin pumps, among other products. Johnson & Johnson said it is seeking a possible sale, joint venture or operating partnerships for LifeScan Inc., Animas Corp. and Calibra Medical Inc. to spark future growth and maximize shareholder value. The company will continue to sell its diabetes treatment Invokana and focus on treating the disease in areas like bariatric surgery. FILE - In this July 16, 2012, file photo, Johnson & Johnson products are displayed in Orlando, Fla. On Tuesday, Jan. 24, 2017, Johnson & Johnson reports financial results. (AP Photo/John Raoux, File) "I want to be clear, we still are very interested in diabetes," Chairman and CEO Alex Gorsky told analysts during a conference call. J&J said last year that it planned to restructure its underperforming medical devices business. Sales from that segment came in nearly flat at $6.44 billion in the fourth quarter. But revenue from other parts of the company grew, helped in part by acquisitions. J&J made several deals in 2016, including a $3.3-billion purchase of hair and personal products maker Vogue International LLC. An 18-percent surge in beauty product sales helped worldwide sales of J&J's consumer segment grow 3.4 percent to $3.43 billion. Pharmaceutical revenue climbed 2.1 percent to $8.23 billion even thoug Continue reading >>
Johnson & Johnson Unit Exits Insulin Pump Business Amid Rising Competition
(Reuters) - Johnson & Johnson’s diabetes care unit, which makes insulin pumps, said on Thursday it would shut its business in United States and Canada amid increased competition and after failing to find a buyer. Animas Corp has selected rival Medtronic Plc as its partner for the device and nearly 90,000 patients using its pumps will be offered the option to transfer to pumps made by Medtronic. J&J has been reviewing strategic options, including a potential sale of its diabetes care division, which includes LifeScan Inc, Animas Corp and Calibra Medical Inc. The division reported sales of $421 million in the second quarter, down 10.6 percent from a year earlier. Analysts said Animas’ exit from the insulin pump business is not surprising. “Animas has not been investing in its product pipeline or aggressively adding patients to its platform over the last year,” William Blair analyst Margaret Kaczor said in a client note. Animas would continue to sell its insulin pumps - Animas Vibe and OneTouch Ping - outside of the United States and Canada, J&J spokeswoman Bridget Doherty told Reuters on Thursday. Brokerage JP Morgan said device makers Medtronic, Insulet Corp and Tandem Diabetes Care Inc could benefit from J&J’s exit from the insulin pump business. However, DexCom Inc, which partnered with Animas, could lose both new and existing blood-glucose monitoring patients, JPMorgan analysts said in a note. Animas said its parent continues to evaluate potential strategic options for blood glucose monitoring business, LifeScan Inc. Shares of J&J and DexCom were marginally down in early morning trading while shares of Medtronic, Insulet and Tandem rose. Continue reading >>
J&j Attracts Chinese Interest For Diabetes Business In Potential $3b To $4b Deal: Sources
J&J attracts Chinese interest for diabetes business in potential $3B to $4B deal: Sources Chinese bidders are circling Johnson & Johnson's diabetes care business in a deal that could fetch up to $4 billion. J&J last year said it was evaluating options for its diabetes care companies, specifically LifeScan, Animas, and Calibra Medical. Among the potential bidders is a consortium being formed by Shenzhen-listed Sinocare. Chinese bidders are circling a diabetes care business owned by the world's largest health-care company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters. New Brunswick, N.J.-based J&J said in January last year it was evaluating options for its diabetes care companies, specifically LifeScan, Animas, and Calibra Medical. One option was a sale of the business, it said. Chinese interest in the J&J unit comes as the market for diabetes care in China is expected to grow rapidly. Almost one in three of the world's diabetes sufferers lives in China, according to World Health Organization estimates. Among the potential bidders is a consortium being formed by Shenzhen-listed Sinocare, which develops and manufactures blood sugar monitoring systems, and China Jianyin Investment (JIC), a unit of sovereign wealth fund China Investment Corp. The group has hired an advisor to work on a bid, according to two sources. "The evaluation of potential strategic options for LifeScan Inc. and Calibra Medical Inc. is ongoing and we do not have an announcement regarding these businesses at this time," J&J said in a statement in response to Reuters request for comment. The company has hired Goldman Sachs to work on the sale, according to three of the people. The bank declined to comment. Sinocare's investors relations offi Continue reading >>
Qualcomm Announces Agreement With Lifescan Inc., A Johnson & Johnson Diabetes Care Company, To Inform Patient Care With Connected Blood Glucose Meters
Qualcomm Announces Agreement with LifeScan Inc., a Johnson & Johnson Diabetes Care Company, to Inform Patient Care with Connected Blood Glucose Meters -- Qualcomm Life to power wireless data capture for LifeScan Incs OneTouch Reveal diabetes management web app -- Qualcomm products mentioned within this press release are offered by Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm Incorporated (NASDAQ: QCOM), through its subsidiary Qualcomm Life, Inc ., announced today its agreement with LifeScan Inc., one of the Johnson & Johnson Diabetes Care Companies (JJDCC), to streamline wireless data capture from LifeScans OneTouch Verio Flex blood glucose meters to physicians to enable more informed care. Qualcomm Lifes medical-grade 2net solution will power the connectivity for efficient, cable-free data collection. By using Qualcomm Lifes medical-grade 2net solution, physicians will be able to conveniently access all of the patients blood glucose data from Lifescans OneTouch Verio Flex blood glucose monitoring system with built-in Bluetooth [i] Smart Technology, which wirelessly sends data to the OneTouch Reveal cloud-based application. Prior to leveraging Qualcomm Lifes 2net solution, the data capture process was manual and cumbersome for physicians, requiring multiple cables and software versions. This new connected diabetes care provides streamlined access to a patients historical and recent blood glucose levels, empowering physicians and the care team to make more proactive, informed care decisions based on data trends. The companies plan to deploy the 2net solution to select physician offices in the Fall of 2017, and expand globally in 2018. Enabling timely access to blood glucose data generates actionable insights for physicians and patients for more informed Continue reading >>
About Us | Lifescan, Inc.
Caring is at the core of everything we do at LifeScan. For over two decades, we have had an unwavering commitment to improving the quality of life for people with diabetes. Every day, more than 5 million people in the U.S. depend on LifeScans OneTouch Brand systems for simple testing and accurate results.. LifeScan is dedicated to best serving the needs of the diabetes community and we recognize the importance of supporting global and national partnerships. In addition to providing monetary and product support, our goal is to increase awareness by teaching people with diabetes and their families that diabetes complications can be reduced with proper diabetes management. At LifeScan, we believe we can make a bigger difference by working together. New breakthroughs are critical to the future of diabetes care. LifeScan is already working to bring you the next important advances in diabetes care. Our development of new technology and manufacturing of innovative blood glucose monitoring devices has made our OneTouch systems the #1 most prescribed brand by Endocrinologists and Primary Care Physicians. These kinds of advances will continue to help eliminate barriers and let patients live life how they choose. A Johnson & Johnson Company since 1986, LifeScan is headquartered in Chesterbrook, Pennsylvania. We also have manufacturing facilities in Puerto Rico and Scotland, and employ more than 3,000 people worldwide. The Credo Read about our guiding principles. Learn more Continue reading >>
Who’s J&j’s Stepchild? Its Consumer Diabetes Device Business
Diabetes is a chronic expensive disease whose burden is great, but it looks like many top companies are looking to get out of the space, or at least parts of it. Consider Exhibit A: Johnson & Johnson announced last week that it’s aiming to prune its consumer diabetes device business that consists of test strips, blood glucose meters, and insulin pumps. Specifically, the New Brunswick company noted that it is exploring strategic options — “operating partnerships, joint ventures or strategic alliances, a sale of the businesses, or other alternatives either separately or together” — for the business that includes the Animas, LifeScan and Calibra Medical, which makes a wearable insulin-patch device, which came to it through an acquisition in 2012. Here’s how Chairman and CEO Alex Gorsky described the decision that the business was no longer core to the company. “Look, it’s always a difficult decision and when you look at your portfolio and as I frequently describe, it is little bit like your children, you love all of them just from time-to-time we are trying to make decisions that we think ultimately are in the best long-term interest of our customers…,” he said in response to an analyst’s question, according to a transcript of the fourth-quarter earnings call from Seeking Alpha. So how did the consumer diabetes device business arrive at the stepchild status? It appears that the rationale for a jettisoning in some shape is rooted in a reimbursement decision from the Centers for Medicare and Medicaid back in 2013 that had a wide-ranging impact. “In 2013 Medicare & Medicaid really slashed reimbursement for those testing strips, which really crippled the business model of these companies which practically gave the meters away and made reoccurring money Continue reading >>
Ceo Gorsky Jj Committed To Diabetes But Looking To Sell Related Device Business
CEO Gorsky: J&J Committed To Diabetes, But Looking To Sell Related Device Business Johnson & Johnson CEO Alex Gorsky says the world's largest healthcare company remains "very committed" in the diabetes space, but is exploring the possibility of divesting its diabetes unit as part of a continuing restructuring of its medical device business. "We are currently evaluating strategic options for our Consumer and Medical Device Diabetes franchise, including LifeScan, Animas, and Calibra," Gorsky said during the company's fourth quarter earnings call. "We are assessing a wide range of options including strategic partnerships and joint ventures and have not set a definitive timeline to complete this review." Gorsky said he is proud of J&J's track record in blood glucose monitoring and insulin pumps, but "we do feel that based upon the broader market dynamics, particularly things such as pricing in certain areas has led us to the point where we say the right thing for us to do is to consider strategic options for these three particular areas of the business." He said J&J still is very much interested in diabetes care, but going forward will concentrate more in developing new products, such as blood glucose-lowering drugs INVOKANA and INVOKANAMET, and products for areas like bariatric surgery. In a phone interview with Bloomberg , J&J CFO Dominic Caruso said the diabetes devices being explored strategically have been hit by significant price declines for several years, and its difficult to fund future innovation. In contrast to the diabetes unit, Gorsky said during the call that he is "very excited about the opportunities we have going forward in Vision Care," especially as J&J acquired AMO in September. J&J's eye business posted a double-digit growth rate in the fourth quarter Continue reading >>
Johnson & Johnson Cautious In Outlook, Shops Diabetes Care
Johnson & Johnson cautious in outlook, shops diabetes care Johnson & Johnson cautious in outlook, shops diabetes care Johnson & Johnson edged above fourth-quarter profit expectations, helped by consumer goods and pharmaceutical growth, but the world's biggest health care products company also gave Wall Street a softer-than-expected 2017 earnings forecast. The maker of Band-Aids and prescription drugs also said Tuesday it was taking another step in restructuring its medical device segment by shopping its diabetes care businesses, which make test strips and insulin pumps, among other products. Johnson & Johnson said it is seeking a possible sale, joint venture or operating partnerships for LifeScan Inc., Animas Corp. and Calibra Medical Inc. to spark future growth and maximize shareholder value. The company will continue to sell its diabetes treatment Invokana and focus on treating the disease in areas like bariatric surgery. "I want to be clear, we still are very interested in diabetes," Chairman and CEO Alex Gorsky told analysts during a conference call. J&J said last year that it planned to restructure its underperforming medical devices business. Sales from that segment came in nearly flat at $6.44 billion in the fourth quarter. But revenue from other parts of the company grew, helped in part by acquisitions. J&J made several deals in 2016, including a $3.3-billion purchase of hair and personal products maker Vogue International LLC. An 18-percent surge in beauty product sales helped worldwide sales of J&J's consumer segment grow 3.4 percent to $3.43 billion. Pharmaceutical revenue climbed 2.1 percent to $8.23 billion even though sales of top-seller Remicade slipped. The biologic immune disorder drug's revenue dropped 3.3 percent to $1.62 billion in the quarter. Remi Continue reading >>
Johnson & Johnson Offers Up Weak 2017 Outlook, Considers Selling Diabetes Units
January 25, 2017 8:53 AM | By Andrea Gonzalez | No comments yet Johnson & Johnson Corp. (J&J) forecast lower-than-expected 2017 sales but managed to beat Wall Street expectations for its 4Q16 earnings. In addition, the New Brunswick, N.J.-based company said it could potentially sell off its diabetes care businesses amid disappointing sales. Tuesdays news was mixed at best. While 4Q16 adjusted earnings per share of $1.58 exceeded analysts consensus estimates of $1.56, J&J drew criticism for its soft 2017 guidance. The firm forecast 2017 adjusted earnings of $6.93 to $7.08 per share below the average analyst estimate of $7.11 per share. Joshua Jennings, an analyst with Cowen and Co. said 2017 guidance tells a deeper than expected deceleration story for the crown jewel Pharma franchise and has offset the strong 4Q print. Part of the reason for the low guidance stems from headwinds J&Js pharmaceuticals division is facing. Particularly, J&Js biologic immune disorder drugs revenue dropped 3.3 percent to $1.62 billion in 4Q16. The firms Remicade had been a strong revenue stream for nearly 18 years but has been taking a pounding from Pfizer Inc.s Inflectra. The New York-based company received approval for the biosimilar in April 2016 but launched the product in October. The products treat rheumatoid arthritis, psoriasis, Crohns disease and colitis. Full-year operational sales growth guidance for [2017] reflects managements expectations for a pharma slowdown as the units significant success has created difficult comps and the Remicade biosimilar launch will have an impact, Jennings said. But all is not lost for J&J in the immunology drug market, said Damien Conover, an analyst with Morning Star. He said other immunology drugs, including Stelara and pipeline drugs guselkumab and Continue reading >>
Focus: Diabetes Treatment
Diabetes incidence is growing around the globe; by 2030, one in every ten people is projected to have diabetes. Diabetes is a growing global epidemic. An estimated 387 million people in the world have diabetes, and the numbers are rising at an alarming speed. Managing this disease requires individually tailored patient plans involving improved lifestyle, diabetes education, balancing nutrition with physical activity and often medication. Even with the disease management tools available today, about 50 percent of people don't have their blood sugar at doctor-recommended levels. The central defect of diabetes is high levels of blood glucose. Blood glucose levels are the result of orchestrated actions by a number of hormones including insulin, incretins and glucagon among others, and organs including the pancreas, liver, kidneys, and muscle and fat tissue. For years, research and treatments have targeted primarily the pancreas, which produces the insulin needed to balance glucose levels in the blood. Janssen focuses on truly transformational therapies within the diabetes space and as the kidneys emerged as a potential target in the treatment of type 2 diabetes because of their role in filtering blood glucose Janssen followed the science and built an aggressive development plan. As such, Janssen launched the first SGLT2 inhibitor in the United States and it has been approved in over 60 countries around the world. However, with the burden of disease so high, we are not content with just this addition to the diabetes treatment paradigm. We continue to pursue novel mechanisms and treatments that will ultimately eliminate the disease. Janssen is proud to be part of the long Johnson & Johnson legacy in diabetes. You can view our full list of products, including our latest diabe Continue reading >>
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes
- Diabetes in Dogs: Symptoms, Causes, & Treatment
Home | Jjmc
We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of the people we serve around the globe. We are known throughout the world for innovative, life-saving medical products and for the values we embrace in making these products available to serve patient needs. We work with partners in health care to touch the lives of Canadians every day. We aim to enhance the health of Canadians by being the most trusted and valued health-care partner. We are an active supporter of community-based organizations, like the United Way, that help advance patient care and quality of life for Canadians. JJMC Makes Major Investment Towards Bariatric Research Study Johnson & Johnson Medical Companies has made a major investment towards funding an extensive bariatric surgery study. Laval University and the Quebec Heart and Lung Institute Research Centre (IUCPQ) are conducting the study, the first of its kind, to research long-term remission of metabolic diseases, such as diabetes, after bariatric surgery. READ MORE . Medical Devices Canada Honours Six Emerging Health Leaders Johnson & Johnson Medical Devices Companies, in partnership with the Canadian College of Health Leaders, presented the annual 2016 Robert Wood Johnson Awards to emerging health leaders at a ceremony in Ottawa, Ontario. READ MORE Johnson & Johnson is one of the worlds most respected employers. We are looking for individuals who are passionate about health care, value scientific innovation, and are deeply committed to enhancing the health of Canadians. This site is published by Johnson & Johnson Medical Products, a Division of Johnson & Johnson Inc. which is solely responsible for its content. It is intended for visitors from Canada only. Third party tradema Continue reading >>
3 Ways Johnson & Johnson Is Revolutionizing Diabetes Care
3 Ways Johnson & Johnson Is Revolutionizing Diabetes Care Johnson & Johnson rarely gets much attention for its efforts in diabetes treatments. Lets take a look at three of the companys interesting new efforts to treat diabetes, and how they could affect companies like AstraZeneca, Bristol-Myers Squibb, Medtronic, DexCom, and Sanofi. When we talk about companies focused on diabetes care, many investors will probably think of insulin makers like Novo Nordisk, Sanofi (NYSE: SNY), and Eli Lilly. Medical giant Johnson & Johnson ( NYSE:JNJ ), best known for its pharmaceuticals, consumer health care products, and medical devices, is often overlooked.However, Johnson & Johnson has slowly but steadily expanded into the diabetes market over the past few years. Let's take a look at three important ways the medical giant is changing diabetes treatments, and how its efforts relate to industry peersAstraZeneca ( NYSE:AZN ), Bristol-Myers Squibb ( NYSE:BMY ), Medtronic ( NYSE:MDT ), DexCom ( NASDAQ:DXCM ), and Sanofi. The first treatment that J&J investors should be familiar with is Invokana, a new treatment for patients with type 2 diabetes that was approved in the U.S. in March 2013 and in the EU in November 2013. Invokana belongs to a brand-new class of drugs known as SGLT2 (sodium glucose co-transporter) inhibitors, which help patients excrete excess blood sugar through the urine. The ultimate hope is that SGLT2 inhibitors could help diabetics achieve better control over their blood sugar levels, which could lead to fewer daily insulin injections. Since this is a potentially game-changing treatment, analysts believe Invokana could eventually generate peak sales of $2.5 billion -- if it overcomes future competitors. For now, Invokana's only competitor is AstraZeneca and Bristol-My Continue reading >>
Animas - Johnson & Johnson Family Of Diabetes Companies | Animas Uk & Ireland
Johnson & Johnson Family of Diabetes Companies Johnson & Johnson Family of Diabetes Companies. Animas is part of the Johnson & Johnson Family of Diabetes Companies (Janssen, LifeScan, Animas and The Johnson & Johnson Institute). With a shared vision of creating a world without limits for people with diabetes, the Johnson & Johnson Family of Diabetes Companies has harnessed the knowledge and expertise of its pharmaceutical, medical device and consumer businesses and strives to improve the lives of people with diabetes by providing comprehensive services, devices, diagnostics and treatments. This cross collaboration of Johnson & Johnson Family of Diabetes Companies (Janssen, LifeScan, Animas and The Johnson & Johnson Institute) ensures the Companys ongoing commitment to serve the needs of people with diabetes across the continuum of care. Today, Johnson & Johnson Family of Diabetes Companies touch more than 10 million people with diabetes worldwide. Animas, a maker of insulin pumps, is dedicated to making diabetes management easier through product innovation, exceptional customer support, and customised education programs. We strive to improve the quality of life of patients and reduce the long-term morbidity of the disease. With headquarters located in Chesterbrook, Pennsylvania, Animas has a distribution presence in 20 countries worldwide. Animas is committed to advancing diabetes management to address unmet patient needs. LifeScan has a 30-year heritage in this disease area and is a leading provider of self-monitoring blood glucose (SMBG) meter systems. The company, which was founded in 1981,currently employs over 2,500 people, has a presence in more than 74 countries worldwide and is continuing to expand in Europe. LifeScans worldwide HQ is located in Wayne, Pennsylv Continue reading >>
J&j Mulls Selling Off Its Diabetes Device Businesses
J&J mulls selling off its diabetes device businesses J&J is considering "strategic options" for its diabetes device businesses because pricing in the diabetes arena has been "challenging." Johnson & Johnson is pondering what to do next with its diabetes device subsidiariesAnimas, LifeScan and Calibra Medical. And while the formation of joint ventures, operating partnerships and divestitures are on the table, CEO Alex Gorsky cautioned that it doesnt mean the conglomerate is committing to any transaction. Animas markets insulin pumps, including one with a remote that wirelessly communicates with the pump to deliver insulin, while LifeScan manufactures blood glucose monitors for both hospital and consumer use. J&J acquired Calibra Medical in 2012 and announced last June that it would roll out the mealtime insulin patch it picked up in the deal. On the fourth-quarter earnings call on Tuesday, Gorsky and Chief Financial Officer Dominic Caruso both said pricing pressure prompted the new considerations. Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go. Continue reading >>
